Drescher CW - Search Results

1

An integrative genomic approach identifies p73 and p63 as activators of miR-200 microRNA family transcription.

Knouf EC, Garg K, Arroyo JD, Correa Y, Sarkar D, Parkin RK, Wurz K, O'Briant KC, Godwin AK, Urban ND, Ruzzo WL, Gentleman R, Drescher CW, Swisher EM, Tewari M. Knouf EC, et al. Among authors: drescher cw. Nucleic Acids Res. 2012 Jan;40(2):499-510. doi: 10.1093/nar/gkr731. Epub 2011 Sep 14. Nucleic Acids Res. 2012. PMID: 21917857 Free PMC article.

2

Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With ERBB2/3 Amplification, Overexpression, or Mutation: Results From the TAPUR Study.

Ahn ER, Rothe M, Mangat PK, Garrett-Mayer E, Ali-Ahmad HM, Chan J, Maitland ML, Patel SR, Reese Z, Balmanoukian AS, Drescher CW, Li R, Tsimberidou AM, Leath CA 3rd, O'Lone R, Grantham GN, Halabi S, Schilsky RL. Ahn ER, et al. Among authors: drescher cw. JCO Precis Oncol. 2023 Apr;7:e2200609. doi: 10.1200/PO.22.00609. JCO Precis Oncol. 2023. PMID: 37027810

3

Use of a stochastic simulation model to identify an efficient protocol for ovarian cancer screening.

Urban N, Drescher C, Etzioni R, Colby C. Urban N, et al. Control Clin Trials. 1997 Jun;18(3):251-70. doi: 10.1016/s0197-2456(96)00233-4. Control Clin Trials. 1997. PMID: 9204225

4

Metastatic placental site trophoblastic tumor: long-term remission in a patient treated with EMA/CO chemotherapy.

Swisher E, Drescher CW. Swisher E, et al. Among authors: drescher cw. Gynecol Oncol. 1998 Jan;68(1):62-5. doi: 10.1006/gyno.1997.4888. Gynecol Oncol. 1998. PMID: 9454662

5

Reported ovarian cancer screening among a population-based sample in Washington state.

Drescher C, Holt SK, Andersen MR, Anderson G, Urban N. Drescher C, et al. Obstet Gynecol. 2000 Jul;96(1):70-4. doi: 10.1016/s0029-7844(00)00849-8. Obstet Gynecol. 2000. PMID: 10862845

6

Worry about ovarian cancer risk and use of ovarian cancer screening by women at risk for ovarian cancer.

Andersen MR, Peacock S, Nelson J, Wilson S, McIntosh M, Drescher C, Urban N. Andersen MR, et al. Gynecol Oncol. 2002 Apr;85(1):3-8. doi: 10.1006/gyno.2001.6556. Gynecol Oncol. 2002. PMID: 11925113

7

The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma.

Hellström I, Raycraft J, Hayden-Ledbetter M, Ledbetter JA, Schummer M, McIntosh M, Drescher C, Urban N, Hellström KE. Hellström I, et al. Cancer Res. 2003 Jul 1;63(13):3695-700. Cancer Res. 2003. PMID: 12839961

8

Compliance of average- and intermediate-risk women to semiannual ovarian cancer screening.

Drescher CW, Nelson J, Peacock S, Andersen MR, McIntosh MW, Urban N. Drescher CW, et al. Cancer Epidemiol Biomarkers Prev. 2004 Apr;13(4):600-6. Cancer Epidemiol Biomarkers Prev. 2004. PMID: 15066925 Clinical Trial.

9

Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma.

McIntosh MW, Drescher C, Karlan B, Scholler N, Urban N, Hellstrom KE, Hellstrom I. McIntosh MW, et al. Gynecol Oncol. 2004 Oct;95(1):9-15. doi: 10.1016/j.ygyno.2004.07.039. Gynecol Oncol. 2004. PMID: 15385104 Free PMC article.

10

Proteins associated with Cisplatin resistance in ovarian cancer cells identified by quantitative proteomic technology and integrated with mRNA expression levels.

Stewart JJ, White JT, Yan X, Collins S, Drescher CW, Urban ND, Hood L, Lin B. Stewart JJ, et al. Among authors: drescher cw. Mol Cell Proteomics. 2006 Mar;5(3):433-43. doi: 10.1074/mcp.M500140-MCP200. Epub 2005 Nov 30. Mol Cell Proteomics. 2006. PMID: 16319398 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

104 results

Search Page

Filters